DSM Biologics and Crucell Announce PER.C6 Licensing Agreement with Biotecnol SA for Antibody Production

09-Jan-2007

DSM Biologics, a business unit of DSM Pharmaceutical Products and Crucell N.V. announced that they have signed a PER.C6® license agreement with Portuguese biotechnology company, Biotecnol SA, and its USA based subsidiary Biotecnol, Inc. This license agreement allows Biotecnol to use the PER.C6® human cell line for preclinical and phase 1 clinical development of its proprietary antibody products, which are composed of Tribodies(TM) and Compact antibodies.

Under the terms of the agreement, Biotecnol will make license payments and annual maintenance fees in exchange for certain rights. Further financial details were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous